68 results about "Antibody titer" patented technology

The invention provides a full-automatic indirect immunofluorescence interpretation method and system, a storage medium and a program product, and relates to the technical field of indirect immunofluorescence detection.The method comprises the steps that when identification information of a target sample is obtained, a plurality of sealed antigen slides are placed in slide carrying groove positions of a bearing platform in batches, and the target sample is obtained; driving the bearing platform through the transmission mechanism to sequentially move the plurality of antigen slides to the imaging area, and performing positioning and fixing operation on the antigen slides entering the imaging area by using the positioning and clamping device; sequentially carrying out multi-view scanning on the antigen slides entering the imaging area to obtain multi-view fluorescence images, and splicing the fluorescence images to generate a fluorescence panoramic image; performing feature extraction on the panoramic image, determining a fluorescence karyotype category and a target fluorescence intensity value, and determining an antibody titer according to the category, the intensity value and dilution information; and performing association mapping on the titer, the category and the panoramic image according to the identification information to generate a fluorescence interpretation result.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention discloses design and synthesis of a hapten of cyromazine, development of a cyromazine artificial antigen and a cyromazine antibody, and application of the cyromazine artificial antigen and the cyromazine antibody in the field of food safety rapid detection. The aminocarboxylic acid modified cyromazine hapten product is prepared through the steps of cyromazine hapten design, connecting arm introduction, synthesis, purification and the like. The cyromazine hapten with the structure is coupled with keyhole limpet hemocyanin to form an artificial immune antigen with immunogenicity, and is coupled with chicken ovalbumin to form an artificial competitive antigen. Tests show that the artificial immune antigen has high immunocompetence and can stimulate an animal immune system to generate an anti-cyromazine antibody, and the titer of an immune Blab / c mouse serum antibody is 16000. The IC50 of an enzyme-linked immunosorbent assay (ELISA) detection method established by the cyromazine artificial competitive antigen and the anti-cyromazine antibody is 5.3 [mu] g / L, and the detection sensitivity of an established gold-labeled immunochromatography detection method reaches 50 [mu] g / L.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

The invention belongs to the technical field of nano biological materials, and particularly relates to a preparation method of cell membrane coated nanoparticles based on solvent equilibrium and sulfydryl anchoring. According to the method, sulfydryl-containing lipid is doped into a membrane system, so that the sulfydryl-containing lipid and the surface of a substrate form a covalent anchor bond to enhance the membrane-substrate binding force, and a small amount of organic solvent is added to improve the fluidity of the lipid and promote spontaneous fusion and uniform spreading of a membrane layer on the surfaces of particles. And centrifuging and washing to obtain the cell membrane nanoparticles with completely coated surfaces. According to the method, high-energy ultrasonic or extrusion treatment is not needed, stable coating can be realized on the premise of maintaining complete composition of membrane protein and lipid, and the adhesion stability of a membrane layer in a high-salt and shearing environment is remarkably improved. The method is suitable for various nano substrates and different morphological structures, and the obtained particles show higher antibody titer and excellent safety in an anti-alpha-hemolysin vaccine model. The invention provides a mild and efficient bionic nano material construction strategy with wide applicability.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

The application discloses a phosphoric acid modified protein or polypeptide, a preparation method thereof and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide is as follows: a compound containing an aldehyde group and a phosphate group is subjected to nucleophilic reaction with a protein or polypeptide to form a Schiff base; a reducing agent is used to reduce the Schiff base, and after post-treatment, the phosphoric acid modified protein or polypeptide is obtained. After the phosphoric acid modified protein product prepared by the method is prepared into a vaccine with an aluminum hydroxide adjuvant and mice are immunized, the antibody titer is significantly increased. This is of great significance for increasing the immune effect, reducing the inoculation dose, saving the antigen amount and improving the immune response of some people or in specific conditions.

The invention discloses an instantaneous transfection method for high-yield CHO-K1 (CHO-K1) by taking linearized PEI (Polyetherimide) as a transfection reagent. The antibody titer reaches about 1g / L within 10 days by replacing a culture medium, zero incubation of a compound, a specific DNA proportion and temperature regulation, the dosage of an expression vector is remarkably reduced, the research and development period is shortened, and the method is suitable for early research and development of antibody drugs and sample preparation.

The invention belongs to the field of medicinal chemistry and pharmacology, and relates to application of a novel glycolipid TLR2 agonist 13-C in preparation of vaccine adjuvants and anti-tumor treatment. The compound is excellent in human TLR2 agonist activity, EC50 reaches 2.2 nM, and the compound is simple in structure, easy to prepare and excellent in solubility and has industrial application potential. In a B16-OVA tumor model, the antibody induction capacity of the compound is superior to that of a positive control drug Diprovocim, and the anti-tumor activity of the compound is more remarkable; in addition, PD-L1 expression of tumor tissue can be effectively down-regulated, and a synergistic anti-tumor effect is generated with a PD-L1 monoclonal antibody Atezolizumab. Besides, 13-C and a vaccine adjuvant QS-21 are combined for use, so that a synergistic enhancement effect is achieved, the antibody titer induced by a vaccine can be remarkably improved, antibody subtypes are enriched, meanwhile, cellular immunity and humoral immunity response of an organism are stimulated, and the effect of dual immune activation is achieved.

Provided are compositions and methods for reducing pre-existing antibodies against viral vector or gene-editing related proteins. The compositions showed reduction in various antibody titers by administration of a liposome composition complexed with a protein or fragment thereof of a viral vector. The liposomes comprise phosphatidylcholine and phosphatidylserine, wherein some or all of the PS is present as lyso-PS. The compositions and methods can be used in conjunction with gene therapy and nucleic acid based vector based vaccinations and therapeutics.

The invention relates to the technical field of antibody titer digitization analysis, in particular to a brucellosis antibody titer digitization analysis system based on a spectrophotometric method.According to the brucellosis antibody titer digitization analysis system, a full-time reaction kinetics absorbance curve is obtained through a data acquisition module; a signal decomposition module is utilized to decouple the signal into a low-frequency trend component and a high-frequency detail component; further identifying a reaction kinetics phase state through a low-frequency trend analysis module to lock an effective reaction interval and generate first-dimension analysis data, and controlling a high-frequency detail analysis module to generate second-dimension analysis data by taking the first-dimension analysis data as a time domain gating basis; finally, the comprehensive evaluation module constructs a coupling weight model based on the reaction kinetics phase state, and fuses the two-dimensional data to generate a comprehensive antibody activity evaluation value; according to the process, a self-adaptive analysis mechanism conforming to a reaction evolution rule is constructed, and accurate determination of the titer of the antibody is realized.

This invention provides a method for detecting AAV antibody titers, belonging to the field of biomedical technology, comprising: S1 preparing serum-free AAV vectors with different MOI values; preparing a mixture containing different volumes of test serum samples and AAV vectors with known MOI values ​​for co-incubation; S2: adding plasmids containing the CRISPR-Cas9 gene editing system to electroporation buffer, performing electroporation on a known number of cells, adding the serum-free AAV vectors and mixture from step S1 to the electroporated cells respectively, and detecting the expression efficiency of the reporter gene after electroporation; S3: calculating the AAV antibody titer in the test serum sample based on the detection results. The main advantage of this invention is that it can display AAV antibody titers digitally and quantitatively, facilitating understanding and communication, and obtaining stable and reliable results using different cell lines and different AAV transduction doses. This method is easy to standardize and validate, saving time, effort, and detection costs compared to traditional methods, and directly reflects antibody neutralizing activity.

The preparation and evaluation method comprises the following steps: 1, extracting a heavy-chain DNA fragment and a light-chain DNA fragment, carrying out recombinant transformation by using an overlapping PCR method to construct an scFv gene, 2, constructing an expression vector, culturing the expression vector, carrying out sequencing identification to obtain an scFv bacterial solution, recombining the scFv bacterial solution with a mouse Fc fragment, and identifying a sequence to obtain an MN8 bacterial solution, the method comprises the following steps: 1, preparing an MN8 bacterial liquid, 2, extracting the MN8 bacterial liquid, 3, carrying out inoculated culture on the MN8 bacterial liquid to obtain an MN8 genetically engineered antibody bacterial liquid, 4, extracting MN8 genetically engineered antibody bacterial liquid plasmids and carrying out transfection expression purification, and 5, carrying out antibody titer and thermal stability determination on the MN8 genetically engineered antibody. The scFv single-chain antibody obtained by recombination according to the method has the advantages of small molecular weight, high penetrability and the like, the stability and the sensitivity of an immunoassay method of the scolosporins can be improved, and a certain basis is provided for rapid determination of the scolosporins.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The present invention relates to a respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell in which the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-A recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, can form a stable F protein trimer with a pre-fusion conformation, and is stable in expression, uniform in form and greatly improved in yield; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.

The invention belongs to the technical field of preparation of vaccine immunologic adjuvants, and discloses a surface-modified aluminum hydroxide nanoparticle adjuvant as well as preparation and application thereof. The aluminum hydroxide-based adjuvant is a next-generation aluminum hydroxide-based adjuvant at an optimal level specially optimized for veterinary vaccines. The formula of the adjuvant solves the limitation of the traditional aluminum hydroxide adjuvant, including poor cellular immune induction and variable efficacy in large animals. The adjuvant promotes balanced Th1 / Th2 immune response, reduces local injection site reaction, and improves the shelf life of the vaccine. The preparation method comprises ultrasonic homogenization and co-precipitation under pH control, vaccine compositions containing the adjuvant, and uses of the adjuvant in prevention of infectious diseases in animal husbandry, companion animals and poultry. Experimental data show that in bovine respiratory disease and avian influenza models, compared with traditional adjuvants, the immunogenicity is excellent, the antibody titer is increased by 3 times, and CD8 + T cell response is enhanced.

The application provides a cell culture protein expression amount and charge heterogeneity synchronous detection method and system, and relates to the technical field of protein detection. Specifically, the method comprises the following steps: sequentially performing gradient elution and chromatography detection on the cell culture, wherein the chromatography column adopts a series connection of an affinity chromatography column and an ion exchange chromatography column. The synchronous detection method solves the blank of synchronous detection of antibody titer and charge heterogeneity in the prior art, improves the efficiency of the traditional analysis mode, and has the advantages of less sample consumption, shorter time consumption, less manpower and instrument resources required, simple structure of the synchronous detection system and convenient operation.

The invention discloses a phosphoric acid modified protein or polypeptide as well as a preparation method and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide comprises the following steps: carrying out nucleophilic reaction on a compound containing an aldehyde group and a phosphate group and protein or polypeptide to form Schiff base; and reducing the Schiff base by using a reducing agent, and carrying out post-treatment to obtain the phosphoric acid modified protein or polypeptide. After the phosphoric acid modified protein product prepared by the method and an aluminum hydroxide adjuvant are prepared into a vaccine and used for immunizing mice, the antibody titer is remarkably increased. The method is of great significance in improving immune effect, reducing inoculant times, saving antigen dosage and improving some people or improving the situation that immune response is weak under specific conditions.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in the treatment of membranous nephropathy. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating membranous nephropathy (MN); (ii) preparing a medicine for reducing the urine protein level; (iii) preparing a medicine for reducing the PLA2R antibody titer; (iv) preparing a medicine for improving the serum albumin level; and / or (v) preparing a medicine for improving the renal function eGFR level. The invention also provides a method for reducing urine protein level, reducing PLA2R antibody titer, increasing serum albumin level and / or increasing renal function eGFR level and a method for preventing and / or treating membranous nephropathy (MN) by using the BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or a CAR-immune cell thereof, or a pharmaceutical composition. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose that patients with high-risk, recurrent or refractory membranous nephropathy can continuously obtain clinical deep relief treatment.

The invention belongs to the technical field of genetic engineering, and particularly relates to a chimeric virus-like particle vaccine of feline coronavirus and feline panleucopenia virus and application of the chimeric virus-like particle vaccine. The invention provides chimeric virus-like particles of feline coronavirus and feline panleucopenia virus. The chimeric virus-like particles contain feline coronavirus type I S protein and feline panleucopenia virus VP2 protein. The invention also provides a preparation method and application of the chimeric virus-like particle. After the vaccine prepared from the chimeric virus-like particles is used for immunizing mice and cats, a high-titer antibody level can be generated, and the organism is stimulated to generate cellular immunity; the immunized cat can effectively resist invasion of cat coronavirus and cat panleucopenia virus. The chimeric virus-like particle has good immunogenicity and can be used for preventing and controlling cat infectious diseases.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

The invention discloses an IgG and IgA antibody detection kit based on porcine rotavirus VP8 protein as well as a preparation method and application of the IgG and IgA antibody detection kit. The kit comprises an elisa plate, positive control serum, negative control serum, an elisa secondary antibody, a sample diluent, a 20-time concentrated washing solution, a substrate solution A, a substrate solution B and a stop solution, wherein the elisa plate is coated with VP8 truncated protein of a porcine rotavirus epidemic strain expressed by mammalian cells. According to the kit, the IgG antibody and the IgA antibody of the porcine rotavirus can be detected at the same time under the condition that only one reagent (enzyme-labeled antibody) is added, and evaluation on the titer of the whole antibody is facilitated. The kit disclosed by the invention is high in sensitivity, high in specificity, good in stability, convenient to operate and relatively high in universality, and has a good market prospect.

The application provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis. The application has the following beneficial effects: the TRPML1 specific small molecule inhibitor ML-SI3 can significantly reduce the serum anti-dsDNA antibody titer level of MRL / lpr lupus mice, reduce the urine albumin / creatinine ratio level, reduce the serum urea nitrogen level, reduce the swelling degree of the spleen and axillary lymph nodes, improve the kidney pathological changes, has a comprehensive protective effect on nephritis of MRL / lpr lupus mice, and provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis, provides a new medicine for treating lupus nephritis, and has good market value and clinical application prospect.

To provide an oral health support method that allows even ordinary users to easily and efficiently predict their risk of future tooth loss, and to provide a system that utilizes information on the risk of future tooth loss to easily and efficiently support the oral health of users. [Solution] A method for supporting oral health, characterized by predicting the risk of tooth loss using antibody titer test results related to oral bacteria and oral quantity test results, and An oral health support system in which a computer predicts the risk of tooth loss from the results of an antibody titer test related to oral bacteria and the results of an oral bacteria quantity test of the user, using a predetermined classification with variables being antibody titers related to oral bacteria and the amount of oral bacteria in the oral cavity. The system then creates information useful for maintaining and promoting oral health, including the predicted risk of tooth loss, and provides it to the user, medical institution, or healthcare professional.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.

The application discloses a kind of functional cationic polymer and its preparation method and application, the functional cationic polymer includes the cationic polymer coupled with targeting polypeptide;The amino acid sequence of the targeting polypeptide is as shown in SEQ ID NO.2;The cationic polymer includes polyamide-amine.The functional cationic polymer provided in the application combines cationic polymer PAA and targeting polypeptide CPE30, can specifically target M cell in mucosa tissue, accelerates the immune response speed of vaccine in organism, and significantly improves antibody titer, and can be used as vaccine adjuvant and widely used in biological medicine field.